文献速递血管炎

伴支气管扩张的MPO-ANCA相关性肾小球肾炎的临床特征与结局:回顾性病例对照研究

Clinical characteristics and outcomes of MPO-ANCA-associated glomerulonephritis with bronchiectasis: A retrospective case-control study.
PubMed 文献 · Semin Arthritis Rheum · 2022-08-17

该回顾性病例对照研究纳入153例MPO-ANCA肾小球肾炎患者,其中52例合并支气管扩张,比较两组临床影像、病理及随访数据。合并支气管扩张者蛋白尿水平较低、eGFR相对较高,间质性肺病和肺气肿发生率较低但肺部感染率较高;支气管扩张严重程度与MPO抗体滴度正相关,多因素分析显示合并支气管扩张者进展至终末期肾病的风险降低(HR=0.542,95%CI 0.299-0.982,p=0.043),但总体生存率无显著差异。

要点

  • 合并支气管扩张的MPO-ANCA肾小球肾炎患者蛋白尿水平较低、eGFR相对较高
  • 支气管扩张严重程度(改良Reiff评分)与MPO抗体滴度正相关(ρ=0.480,p<0.001)
  • 多因素分析显示合并支气管扩张与进展至终末期肾病风险降低相关(HR=0.542,95%CI 0.299-0.982,p=0.043)

核心结论

  • 在MPO-ANCA肾小球肾炎患者中,支气管扩张严重程度与抗MPO抗体滴度相关。
  • 合并支气管扩张与较好的肾脏预后相关,但未改善总体生存率。

研究设计与样本

  • 回顾性病例对照研究,纳入153例MPO-ANCA肾小球肾炎患者,其中52例合并支气管扩张,比较两组临床影像、病理及随访资料,以进展至终末期肾病和死亡为终点事件。

主要发现

  • 合并支气管扩张组较单纯MPO-ANCA肾小球肾炎组蛋白尿水平较低(p=0.019),eGFR水平相对较高。
  • 合并支气管扩张组间质性肺病发生率较低(p<0.001),肺气肿发生率较低(p=0.016),肺部感染率较高(p<0.001)。
  • 支气管扩张严重程度(改良Reiff评分)与MPO抗体滴度正相关(ρ=0.480,p<0.001),但与较短的肾脏生存期无关。
  • 多因素分析显示合并支气管扩张组进展至终末期肾病的风险降低(p=0.043,HR=0.542,95%CI 0.299-0.982)。
  • 合并支气管扩张组与单纯MPO-ANCA肾小球肾炎组1年总体生存率分别为88.2%与83.7%(p=0.431),3年总体生存率分别为77.3%与67.2%(p=0.241)。

关键数值与推荐

  • 合并支气管扩张组蛋白尿水平低于单纯MPO-ANCA肾小球肾炎组(p=0.019)。
  • 合并支气管扩张组间质性肺病发生率低于单纯组(p<0.001),肺气肿发生率低于单纯组(p=0.016),肺部感染率高于单纯组(p<0.001)。
  • 支气管扩张严重程度(改良Reiff评分)与MPO抗体滴度正相关(ρ=0.480,p<0.001)。
  • 多因素分析中合并支气管扩张与进展至终末期肾病风险降低相关(p=0.043,HR=0.542,95%CI 0.299-0.982)。
  • 合并支气管扩张组与单纯组1年总体生存率分别为88.2%与83.7%(p=0.431),3年总体生存率分别为77.3%与67.2%(p=0.241)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association of bronchiectasis with myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (MPO-AAV) has been widely described in recent studies. However, the clinical features and outcomes of MPO-ANCA-associated glomerulonephritis (MPO-ANCA GN) patients with bronchiectasis remain enigmatic. METHODS: MPO-ANCA GN patients with bronchiectasis were compared to MPO-ANCA GN patients alone. Clinical imaging, pathological tests, and follow-up examination data of patients were collected retrospectively. Progression to end-stage renal disease (ESRD) and death was treated as endpoint events. RESULTS: 153 cases (52 patients with bronchiectasis) were included in this study. Compared to MPO-ANCA GN patients alone, MPO-ANCA GN patients with bronchiectasis exhibited a lower level of proteinuria (p = 0.019) and relatively higher eGFR level. MPO-ANCA GN patients with bronchiectasis had less frequent incidences of interstitial lung disease (ILD) and emphysema (p<0.001, p = 0.016, respectively) but with higher rates of pulmonary infection (p<0.001). Bronchiectasis severity (the modified Reiff score) was positively correlated with MPO antibody titers (ρ=0.480, p<0.001), but not with shorter renal survival. A relatively higher remission rate was been seen in MPO-ANCA GN patients with bronchiectasis, who showed reduced susceptibility in progressing to ESRD in multivariate analysis (p = 0.043, HR=0.542, 95% CI 0.299-0.982). One-and three-year overall survival rates were 88.2% and 77.3% for MPO-ANCA GN with bronchiectasis cases versus 83.7% and 67.2% for MPO-ANCA GN patients alone (p = 0.431, p = 0.241, respectively). CONCLUSION: The severity of bronchiectasis was correlated with anti-MPO antibody titers in MPO-ANCA GN patients. For MPO-ANCA GN patients, bronchiectasis associated with good renal prognosis, but it did not improve overall survival.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Luo L, Li H, Tang J, et al. Clinical characteristics and outcomes of MPO-ANCA-associated glomerulonephritis with bronchiectasis: A retrospective case-control study. Semin Arthritis Rheum. 2022. PMID: 36058136. doi:10.1016/j.semarthrit.2022.152082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。